ZIKAlliance is an international project bringing together 52 academic partners, including CEA, with three main goals:
- understanding the impact of infection by the Zika virus during pregnancy and the medium-term effects in newborns,
- studying the infection's propagation in humans and the environment,
- developing a response to the threat of epidemics in Latin America and the Caribbean, in collaboration with the ZIKAction and ZikaPLAN projects.
Within this framework, CEA-Joliot Institute will have the task of producing monoclonal antibodies directed against the virus, and to make them available to ZIKAlliance's entire scientific community.
The partners met last December in São Paulo, Brazil, to launch the project and coordinate their work. This project is financed by the European Union's H2020 project.